Safety of Tinted Soft Scleral Eye Shields When IPL is Applied on Eyelids
- Conditions
- Dry Eye DiseaseMeibomian Gland Dysfunction
- Interventions
- Combination Product: Protection of eyes with tinted soft scleral eye shields
- Registration Number
- NCT05168670
- Lead Sponsor
- Lumenis Be Ltd.
- Brief Summary
The purpose of this study is to verify the safety of tinted soft scleral eye shields when IPL is applied directly on eyelids.
- Detailed Description
Patients with dry eye disease due to meibomian gland dysfunction will be treated with one session of IPL applied directly on upper and lower eyelids, when eyes are protected with tinted soft scleral eye shields which prevent IPL from penetrating into ocular structures. Ocular structures will be examined with various tests (including: biomicroscopy, OCT and specular microscopy) at baseline and at 10 minutes after IPL, 24 hours after IPL, and 7 days after IPL. In addition, visual acuity will be measured at each of these times, and the patient will report of any visual symptoms at each of these times. The primary objective is to verify that no morphological or functional changes occur between the baseline and the 7 days follow-up visit.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
- Subject is able to read, understand and sign an IC form
- 22 or older
- Self-assessed symptoms are consistent with dry eye (SPEED score ≥ 10)
- Signs of MGD, as detected in biomicroscopy
- Fitzpatrick skin type I-V
- Subject is willing to comply with all study procedures, including return to the clinic 1 day and 1 week after the first and only treatment within the scope of the study
-
• Fitzpatrick skin type VI
- Ocular surgery or eyelid surgery, within 3 months prior to screening
- Recent ocular trauma, within 3 months prior to screening
- Pre-cancerous lesions, skin cancer or pigmented lesions in the planned treatment area
- Severe active allergies, or other severe uncontrolled eye disorders affecting the ocular surface
- Uncontrolled infections or uncontrolled immunosuppressive diseases
- Subjects with ocular infections requiring the use of antibiotic treatment, within 3 months prior to screening
- Legally blind in either eye
- Ocular surface abnormality that may compromise corneal integrity in either eye (e.g., keratoconus, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal fluorescein staining, map dot fingerprint dystrophy, prior chemical burn)
- Eyelid abnormalities that affect lid function in either eye, including: entropion, ectropion, tumor, blepharospasm, lagophthalmos, severe trichiasis, and severe ptosis
- Prior history of cold sores or rashes in the perioral area or in the planned treatment area that could be stimulated by light at a wavelength of 560 nm to 1200 nm, including: Herpes simplex 1 & 2, Systemic Lupus erythematosus, and porphyria
- Within 3 months prior to screening, use of photosensitive medication and/or herbs that may cause sensitivity to 560-1200 nm light exposure, including: Isotretinoin, Tetracycline, Doxycycline, and St. John's Wort
- Over exposure to sun, within 4 weeks prior to screening
- Moderate to severely compromised corneal health as assessed by corneal fluorescein staining
- Trans-illumination defects
- Anisocoria or pupil deformation
- Anterior chamber inflammation
- Media opacities (cataract, posterior capsule opacification, corneal edema, etc.) that preclude clear visualization of the anterior segment and retina
- Any condition revealed whereby the investigator deems the subject inappropriate for this study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Study arm Protection of eyes with tinted soft scleral eye shields Protection of eyes with tinted soft scleral eye shields followed by IPL administration directly on eyelids
- Primary Outcome Measures
Name Time Method Ophthalmic morphological changes at 1 week after intervention 1 week Opinion of the study investigator (yes/no) whether there was any change in ocular structures at 1 week after intervention (based on a series of tests including biomicroscopy, corneal fluorescein staining, anterior segment OCT, posterior segment OCT, and specular microscopy)
- Secondary Outcome Measures
Name Time Method Ophthalmic morphological changes at 10 minutes after intervention 10 minutes Opinion of the study investigator (yes/no) whether there was any change in ocular structures at 10 minutes after intervention (based on a series of tests including biomicroscopy, corneal fluorescein staining, anterior segment OCT, posterior segment OCT, and specular microscopy)
Subjective functional change at 1 day after intervention 1 day Change in perception of visual symptoms (Visual analog scale) at 1 day
after interventionObjective functional change at 10 minutes after intervention 10 minutes Change in best-corrected visual acuity (ETDRS chart) at 10 minutes after intervention
Objective functional change at 1 week after intervention 1 week Change in best-corrected visual acuity (ETDRS chart) at 1 week after intervention
Ophthalmic morphological changes at 24 hours after intervention 24 hours Opinion of the study investigator (yes/no) whether there was any change in ocular structures at 24 hours after intervention (based on a series of tests including biomicroscopy, corneal fluorescein staining, anterior segment OCT, posterior segment OCT, and specular microscopy)
Objective functional change at 24 hours after intervention 24 hours Change in best-corrected visual acuity (ETDRS chart) at 24 hours after intervention
Subjective functional change at 10 minutes after intervention 10 minutes Change in perception of visual symptoms (Visual analog scale) at 10 minutes after intervention
Subjective functional change at 1 week after intervention 1 week Change in perception of visual symptoms (Visual analog scale) at 1 week
after intervention
Trial Locations
- Locations (1)
Toyos Clinic
🇺🇸Nashville, Tennessee, United States